Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    TGC12301
Previous Study | Return to List | Next Study

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03203330
Recruitment Status : Active, not recruiting
First Posted : June 29, 2017
Last Update Posted : May 13, 2020
Sponsor:
Information provided by (Responsible Party):
Kolon TissueGene, Inc.

Brief Summary:
A randomized, double-blind, placebo-controlled, multi-center, phase 3 study to determine the safety and efficacy of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or 2 of the knee joint. TG-C is to be administered by a single intra-articular injection to the damaged joint area via ultrasound guidance. Patients will be followed for 24 months for safety and efficacy.

Condition or disease Intervention/treatment Phase
Degenerative Osteoarthritis Biological: TG-C Biological: Placebo Control Phase 3

Detailed Description:
This protocol is designed to assess the safety and efficacy of TG-C in treating symptoms of osteoarthritis of the knee and determining disease modifying effects of TG-C. This study is intended for the treatment of patients with KL Grade 2 and 3 osteoarthritis and OARSI JSN Grade 1 and 2. Assessments will be made on both the symptomatic effects of pain (VAS), function (WOMAC), and Quality of Life (SF-12) as well as the physical effects (JSW, MRI evaluations of whole knee joint organ tissues and structure) and biochemical biomarkers. This is a placebo-controlled study, TG-C will be compared to normal saline as a control. Additionally, this protocol is designed to evaluate the safety of TG-C. Safety will be evaluated by observation of the injection site for irritation or other effects, the incidence and severity of adverse events, and changes in physical examination findings, radiographic criteria, and laboratory tests. Patients will be followed for 24 months for both safety and efficacy with annual cancer surveillance questionnaires through 15 years post dosing for subjects who do not enroll in the Long Term Safety study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 510 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double-blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade (KLG) 2 or 3 Osteoarthritis of the Knee
Actual Study Start Date : October 30, 2018
Estimated Primary Completion Date : October 30, 2023
Estimated Study Completion Date : October 30, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Active Comparator: Active Treatment (TG-C)
TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
Biological: TG-C
2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
Other Name: TissueGene-C

Placebo Comparator: Placebo Control (Normal Saline)
Normal saline, single 2 mL intraarticular injection
Biological: Placebo Control
2 mL normal saline injection
Other Name: Normal Saline




Primary Outcome Measures :
  1. Change in Knee Function as Assessed by the Western Ontario and McMaster Universities Index (WOMAC) [ Time Frame: 12 months ]
    Assessment of change from baseline in target knee function using the WOMAC Osteoarthritis Index. The WOMAC is a proprietary set of standardized questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee including pain, stiffness, and physical functioning of the joints. The response to the questions is in the form of a checked box associated with the response; None, Mild, Moderate, Severe and Extreme.

  2. Change in Knee Pain as Assessed by VAS [ Time Frame: 12 months ]
    Assessment of change from baseline in target knee pain using the Visual Analog Scale (VAS). The VAS is a method for the assessment of the intensity of pain. The VAS is a horizontal line, 100 mm in length and anchored by word descriptors at each end (no pain, very severe pain). The patient marks on the line at the point that represents their current state. The VAS score is determined by measuring in millimeters from the left hand end to the point of the mark. The score ranges from "0" or no pain to "100" very severe pain.


Secondary Outcome Measures :
  1. MRI Assessment of Target Knee [ Time Frame: 12 months ]
    Evaluation of the features of OA, as determined by structural changes of the knee joint, assessed by MRI

  2. PCS of the SF-12 Questionnaire [ Time Frame: 12 months ]
    Evaluation the Health-Related Quality of Life (HRQoL) as measured by the physical component score (PCS) of the 12-Item Short-Form Health Survey version 2 (SF-12v2®) questionnaire

  3. WOMAC Total Score [ Time Frame: 24 months ]
    Evaluation of the efficacy of TG-C with regard to knee function via WOMAC total score

  4. Health Assessment Questionnaire Disability Index [ Time Frame: 12 months ]
    Evaluation of the HRQoL as measured by the Health Assessment Questionnaire - Disability Index (HAQ-DI)


Other Outcome Measures:
  1. Radiography for Structural Change in Knee Joint [ Time Frame: Through 24 months ]
    Evaluate structural changes of the knee joint as determined by radiography (X-ray)

  2. Efficacy of TG-C with Regard to Knee Function via WOMAC Total Score [ Time Frame: At Months 3, 6, 9 and 18 ]
    Evaluation of the efficacy of TG-C with regard to knee function via WOMAC total score

  3. Efficacy of TG-C with Regard to Knee Function via WOMAC Pain, Function, and Stiffness Scores [ Time Frame: Through 24 months ]
    Evaluate the efficacy of TG-C with regard to knee function via WOMAC® pain, function, and stiffness scores

  4. Efficacy of TG-C with Regard to Knee Function via VAS Pain Score [ Time Frame: At Day 1, Week 1, and Months 1, 3, 6, 9, 18 and 24 ]
    Evaluation of the efficacy of TG-C with regard to knee function via VAS pain score at time points other than Month 12

  5. OMERACT-OARSI Responder Analysis [ Time Frame: 12 and 24 months ]
    Analysis of response using the Outcomes Measures in Rheumatoid Arthritis Clinical Trials (OMERACT)-OARSI responder criteria



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged 40 or older
  • BMI between 18.5 and 40
  • KL Grade 2 or 3 knee OA
  • OARSI Grade 1 or 2 medial JSN
  • Pain >= 40 on VAS scale
  • WOMAC score <=70 for target knee
  • Written informed consent
  • Using birth control

Exclusion Criteria:

  • Knee symptoms that result in difficulty or inability to walk
  • Knee effusion >2+
  • Has Grade 0 OARSI JSN or atrophic OA
  • Has a score of >=5 on the cartilage feature of the WORMS at Screening
  • MRI exam indicates fracture or tumor
  • Has a positive result on RCR testing at Screening
  • Has taken NSAIDS with 14 days of baseline
  • Has taken steroidal anti-inflammatory medication within 2 months of baseline
  • Chronic (>21 days) narcotic use
  • Recent history (within 1 year) of drug or alcohol abuse
  • Pregnant or lactating
  • Has received injection to target knee within 2 months prior to study entry
  • History of various disorders of the knee including but not limited to rheumatoid arthritis, psoriatic arthritis, autoimmune OA, chondrocalcinosis, gout, hemochromatosis, villonodular synovitis, or synovial chondromatosis
  • Severe hip osteoarthritis ipsilateral to the target knee
  • Ongoing infection disease including but not limited to HIV, Hepatitis B or C.
  • Clinically significant congestive heart failure hepatic disease, kidney disease, adrenal insufficiency, acromegaly, uncontrolled hyper- or hypothyroidism, or non-specified uncontrolled endocrine disorder
  • Uncontrolled diabetes based on a HbA1c > 8% at screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03203330


Locations
Layout table for location information
United States, Alabama
Central Research Associates, Inc
Birmingham, Alabama, United States, 35205
United States, California
Orthopedic Pain Specialists
Santa Monica, California, United States, 90403
United States, Florida
Clinical Research of West Florida
Tampa, Florida, United States, 33606
United States, Missouri
The Center for Pharmaceutical Research
Kansas City, Missouri, United States, 64114
United States, Nebraska
Physician Research Collaboration
Lincoln, Nebraska, United States, 68516
United States, New York
Ainsworth Institute of Pain Management
New York, New York, United States, 10022
North Shore Long Island Jewish - Lenox Hill - Research
New York, New York, United States, 10075
United States, Pennsylvania
University Orthopedics Center
Altoona, Pennsylvania, United States, 16602
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
University Orthopedics
State College, Pennsylvania, United States, 16801
United States, South Carolina
Lowcountry Orthopaedics and Sports Medicine
Charleston, South Carolina, United States, 29406
United States, Utah
Physicians' Research Options, LLC
Draper, Utah, United States, 84020
Sponsors and Collaborators
Kolon TissueGene, Inc.
Investigators
Layout table for investigator information
Study Chair: Moon Jong Noh, PhD Kolon TissueGene, Inc.
Layout table for additonal information
Responsible Party: Kolon TissueGene, Inc.
ClinicalTrials.gov Identifier: NCT03203330    
Other Study ID Numbers: TGC-12301
First Posted: June 29, 2017    Key Record Dates
Last Update Posted: May 13, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases